On Friday, Ocular Therapeutix Inc (NASDAQ: OCUL) opened lower -7.66% from the last session, before settling in for the closing price of $9.92. Price fluctuations for OCUL have ranged from $2.05 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 121.20% over the last five years. Company’s average yearly earnings per share was noted -18.07% at the time writing. With a float of $135.67 million, this company’s outstanding shares have now reached $157.22 million.
The firm has a total of 267 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.57%, operating margin of -230.41%, and the pretax margin is -284.38%.
Ocular Therapeutix Inc (OCUL) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ocular Therapeutix Inc is 13.42%, while institutional ownership is 77.36%. The most recent insider transaction that took place on Oct 16 ’24, was worth 134,269. Before that another transaction happened on Aug 23 ’24, when Company’s Chief Strategy Officer sold 1,832 for $9.02, making the entire transaction worth $16,525. This insider now owns 176,194 shares in total.
Ocular Therapeutix Inc (OCUL) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.35 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.22) by -0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -18.07% per share during the next fiscal year.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Check out the current performance indicators for Ocular Therapeutix Inc (OCUL). In the past quarter, the stock posted a quick ratio of 12.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -1.07 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Analysing the last 5-days average volume posted by the [Ocular Therapeutix Inc, OCUL], we can find that recorded value of 1.01 million was lower than the volume posted last year of 1.86 million. As of the previous 9 days, the stock’s Stochastic %D was 22.61%. Additionally, its Average True Range was 0.58.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 51.17%, which indicates a significant increase from 0.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.22% in the past 14 days, which was lower than the 56.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.88, while its 200-day Moving Average is $8.03. Now, the first resistance to watch is $9.74. This is followed by the second major resistance level at $10.33. The third major resistance level sits at $10.63. If the price goes on to break the first support level at $8.86, it is likely to go to the next support level at $8.56. Now, if the price goes above the second support level, the third support stands at $7.98.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are currently 155,922K shares outstanding in the company with a market cap of 1.33 billion. Presently, the company’s annual sales total 58,440 K according to its annual income of -80,740 K. Last quarter, the company’s sales amounted to 16,440 K and its income totaled -43,780 K.
